Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oral semaglutide for weight loss in adults with overweight or obesity
NL-OMON61455Phase 3Recruiting
- Sponsor
- Novo Nordisk
- Start
- Aug 2026
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of semaglutide in obesity and Overweight, sponsored by Novo Nordisk. Primary endpoint: Relative change in body weight. Started Aug 2026; status: recruiting.
02
Drugs
03
Conditions
obesityOverweight
Beyond the preview
Go deeper on NL-OMON61455.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON61455.